日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Applying Precision Medicine to the Heterogeneity of Asthma Attacks

将精准医学应用于哮喘发作的异质性研究

期刊:Chest
影响因子:8.6
doi:10.1016/j.chest.2025.11.013
Celis-Preciado, Carlos Andres; Ben Hamou-Kuijpers, Elsa; Ramakrishnan, Sanjay; Howell, Imran; Wechsler, Michael E; Akuthota, Praveen; Couillard, Simon
哮喘
发表日期：2026
文献求助 收藏

Clinical relevance of CompEx Asthma and impact on disease trajectory: benralizumab effect

CompEx哮喘的临床意义及其对疾病进程的影响：贝那利珠单抗的疗效

期刊:Erj Open Research
影响因子:4
doi:10.1183/23120541.00486-2025
Bolton, Clare; Akuthota, Praveen; Lugogo, Njira; Barker, Peter; Bengtsson, Thomas; Peterson, Stefan; Siddiqui, Salman; Da Silva, Carla A
哮喘
发表日期：2026
文献求助 收藏

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA

一项 IIa 期随机、双盲、安慰剂对照研究，旨在评估 londamocitinib (AZD4604) 每日两次，持续 12 周，治疗中高剂量吸入性糖皮质激素-长效β2受体激动剂 (ICS-LABA) 控制不佳的中重度哮喘成人患者的疗效和安全性。

期刊:Bmj Open Respiratory Research
影响因子:3.4
doi:10.1136/bmjresp-2025-003589
Mustapa, Mohd Nubli; Hughes, Rod; Jensen, Tina J; Dosanjh, Davinder P; Konstantinidis, Kyriakos V; Jonsson, Julia; Nemes, Szilárd; Jevnikar, Zala; Jones, Michael; Adams, Amanda; Belvisi, Maria G; Akuthota, Praveen; Kocks, Janwillem W H
信号转导
哮喘
免疫/内分泌
发表日期：2026
文献求助 收藏

CompEx Asthma: is it time for a change in clinical trials?

CompEx Asthma：临床试验是否需要变革？

期刊:European Respiratory Journal
影响因子:21
doi:10.1183/13993003.00470-2025
Wilkinson, Tom M A; Akuthota, Praveen
发表日期：2025
文献求助 收藏

Con: clinical remission in asthma - not yet there

缺点：哮喘的临床缓解——尚未实现

期刊:European Respiratory Review
影响因子:10.4
doi:10.1183/16000617.0182-2024
Eggert, Lauren; Rhoads, Sarah; Wechsler, Michael E; Akuthota, Praveen
哮喘
发表日期：2025
文献求助 收藏

Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

更正：Tezepelumab 在美国重度哮喘患者不同人群中的有效性和安全性：PASSAGE 研究的初步结果

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03316-2
Lugogo, Njira L; Akuthota, Praveen; Sumino, Kaharu; Mathur, Sameer K; Burnette, Autumn F; Lindsley, Andrew W; Llanos, Jean-Pierre; Marchese, Claudio; Ambrose, Christopher S; Emmanuel, Benjamin
哮喘
发表日期：2025
文献求助 收藏

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

Tezepelumab 在美国重度哮喘患者不同人群中的有效性和安全性：PASSAGE 研究的初步结果

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03231-6
Lugogo, Njira L; Akuthota, Praveen; Sumino, Kaharu; Mathur, Sameer K; Burnette, Autumn F; Lindsley, Andrew W; Llanos, Jean-Pierre; Marchese, Claudio; Ambrose, Christopher S; Emmanuel, Benjamin
哮喘
发表日期：2025
文献求助 收藏

The Role of Incretins in Obstructive Sleep Apnea "GLP1RAs and GLP1RA/GIPRAs in OSA"

肠促胰岛素在阻塞性睡眠呼吸暂停中的作用“GLP-1RA 和 GLP-1RA/GIPRA 在 OSA 中的作用”

期刊:Journal of Diabetes
影响因子:3.7
doi:10.1111/1753-0407.70170
Fuentes, Ana Lucia; Dhami, Gurleen; Pettus, Jeremy; Akuthota, Praveen; Malhotra, Atul
GIP
GLP-1
免疫/内分泌
发表日期：2025
文献求助 收藏

Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA

初级保健医生在诊断和治疗罕见嗜酸性粒细胞疾病（如嗜酸性粒细胞增多症和嗜酸性粒细胞性肉芽肿性血管炎）方面发挥着至关重要的作用。

期刊:Frontiers in Medicine
影响因子:3
doi:10.3389/fmed.2025.1568770
Shum, Mili; Gewurz-Singer, Ora; Silver, Jared; Akuthota, Praveen
炎症/感染
细胞生物学
粒细胞
发表日期：2025
文献求助 收藏

Asthma innovations from the second International Collaborative Asthma Network (ICAN) forum

第二届国际哮喘合作网络（ICAN）论坛上的哮喘创新成果

期刊:Journal of Asthma
影响因子:1.3
doi:10.1080/02770903.2024.2403011
Jarjour, Nizar N; Winders, Tonya; Hansen, Ann M; Akuthota, Praveen; Chung, Kian Fan; Durrington, Hannah; Fowler, Stephen J; Gaston, Benjamin; Mendonca, Eneida A; Siddiqui, Salman; Walker, Samantha; Zein, Joe; Djukanovic, Ratko
哮喘
发表日期：2025
文献求助 收藏